Cargando…

Polyphenols as Promising Drugs against Main Breast Cancer Signatures

Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state,...

Descripción completa

Detalles Bibliográficos
Autores principales: Losada-Echeberría, María, Herranz-López, María, Micol, Vicente, Barrajón-Catalán, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745498/
https://www.ncbi.nlm.nih.gov/pubmed/29112149
http://dx.doi.org/10.3390/antiox6040088
_version_ 1783288916310228992
author Losada-Echeberría, María
Herranz-López, María
Micol, Vicente
Barrajón-Catalán, Enrique
author_facet Losada-Echeberría, María
Herranz-López, María
Micol, Vicente
Barrajón-Catalán, Enrique
author_sort Losada-Echeberría, María
collection PubMed
description Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state, cell cycle alterations, increased proliferation and an inflammatory status. On the other hand, breast cancer shows differential molecular subtypes that determine its prognosis and treatment. These are characterized mainly by hormone receptors especially estrogen receptors (ERs) and epidermal growth factor receptor 2 (HER2). Tumors with none of these receptors are classified as triple negative breast cancer (TNBC) and are associated with a worse prognosis. The success of treatments partially depends on their specificity and the adequate molecular classification of tumors. New advances in anticancer drug discovery using natural compounds have been made in the last few decades, and polyphenols have emerged as promising molecules. They may act on various molecular targets because of their promiscuous behavior, presenting several physiological effects, some of which confer antitumor activity. This review analyzes the accumulated evidence of the antitumor effects of plant polyphenols on breast cancer, with special attention to their activity on ERs and HER2 targets and also covering different aspects such as redox balance, uncontrolled proliferation and chronic inflammation.
format Online
Article
Text
id pubmed-5745498
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57454982018-01-02 Polyphenols as Promising Drugs against Main Breast Cancer Signatures Losada-Echeberría, María Herranz-López, María Micol, Vicente Barrajón-Catalán, Enrique Antioxidants (Basel) Review Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state, cell cycle alterations, increased proliferation and an inflammatory status. On the other hand, breast cancer shows differential molecular subtypes that determine its prognosis and treatment. These are characterized mainly by hormone receptors especially estrogen receptors (ERs) and epidermal growth factor receptor 2 (HER2). Tumors with none of these receptors are classified as triple negative breast cancer (TNBC) and are associated with a worse prognosis. The success of treatments partially depends on their specificity and the adequate molecular classification of tumors. New advances in anticancer drug discovery using natural compounds have been made in the last few decades, and polyphenols have emerged as promising molecules. They may act on various molecular targets because of their promiscuous behavior, presenting several physiological effects, some of which confer antitumor activity. This review analyzes the accumulated evidence of the antitumor effects of plant polyphenols on breast cancer, with special attention to their activity on ERs and HER2 targets and also covering different aspects such as redox balance, uncontrolled proliferation and chronic inflammation. MDPI 2017-11-07 /pmc/articles/PMC5745498/ /pubmed/29112149 http://dx.doi.org/10.3390/antiox6040088 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Losada-Echeberría, María
Herranz-López, María
Micol, Vicente
Barrajón-Catalán, Enrique
Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title_full Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title_fullStr Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title_full_unstemmed Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title_short Polyphenols as Promising Drugs against Main Breast Cancer Signatures
title_sort polyphenols as promising drugs against main breast cancer signatures
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745498/
https://www.ncbi.nlm.nih.gov/pubmed/29112149
http://dx.doi.org/10.3390/antiox6040088
work_keys_str_mv AT losadaecheberriamaria polyphenolsaspromisingdrugsagainstmainbreastcancersignatures
AT herranzlopezmaria polyphenolsaspromisingdrugsagainstmainbreastcancersignatures
AT micolvicente polyphenolsaspromisingdrugsagainstmainbreastcancersignatures
AT barrajoncatalanenrique polyphenolsaspromisingdrugsagainstmainbreastcancersignatures